TAL61 demonstrated significant anti-tumor properties with strong tolerability in patient-derived xenograft models of chordoma TAL61 showed robust single-agent activity in Brachyury-positive non-small ...

Heart attacks remain a significant health concern in the United States. According to the Centers for Disease Control and ...

Researchers have developed a new therapy that can be injected intravenously right after a heart attack to promote healing and ...

RNA-based technologies are a powerful molecular biology toolbox, empowering scientists to decipher the complexities of living ...

In further support of that finding, the researchers determined—with the help of AI—that PHGDH plays a previously undiscovered ...

In a phase 1 trial involving 40 patients, the research group investigated the use of T cell receptor (TCR)-engineered T cells. Using genetic ...

With this level of control, scientists can fine-tune how nanomedicines interact with the human body. These new designs are ...

Scientists have developed a powerful new injectable treatment that, when administered after a heart attack, helps the heart ...

Aclaris Therapeutics, Inc.’s ACRS share price has surged by 6.72%, which has investors questioning if this is right time to sell.

A joint research team has developed a modular protein adapter technology that enables the stable attachment of various ...

A small case-control study found potential molecular evidence that links human papillomavirus (HPV) to thyroid eye disease ...